So far, our work shows that [1] NSMCE2 and MAL2 genes are regulated by SEs at the transcript level in breast cancers; [2] the expression of these genes can be reduced by BET inhibition; and [3] high NSMCE2 expression correlates to poor response to chemotherapy in grade III TN or HER2 + breast cancer patients. This evidence concerns the gene MAL2 and breast carcinoma.